Fundraising Fox

Arnatar Therapeutics

8 known investors

arnatar.com ↗

Arnatar develops RNA therapeutics using its DARGER platform, which combines gene silencing via siRNA with protein upregulation through antisense oligonucleotides (ACT-UP1). The company targets cardiovascular, metabolic, CNS, and rare diseases.

BiotechDeep Tech

Investors · 8

3E Bioventures CapitalPalo Alto
F-Prime Capital PartnersCambridge · $3M – $10M
Apricot Capitalreported · 2 sourcesShanghai
Eight Roads VenturesreportedBangalore · $5M – $30M
F-Prime Capitalreported
Gaorong VenturesreportedGeorge Town, Grand Cayman · $2.8M – $120M
Legend Starreported北京 · $425K – $112M
New Alliance CapitalreportedShanghai

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Top 5 Companies Likely to Transact (August 18, 2026)dakota.com · Aug 2026MagStone Law provided legal services for Arnatar Therapeutics' $50 million Series A financing.magstonelaw.com · Mar 2026Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4globenewswire.com · Aug 2025Arnatar unveils with $52M, dual-modality RNA platform and rare disease assetfiercebiotech.com · Aug 2025Arnatar Debuts With $52M To Advance RNA Therapies That Go Beyond Silencing - BioSpacebiospace.com · Aug 2025Arnatar Therapeutics Emerges With $52M Series A Raised in 2024finsmes.com · Aug 2025

Frequently asked questions

What does Arnatar Therapeutics do?
Arnatar develops RNA therapeutics using its DARGER platform, which combines gene silencing via siRNA with protein upregulation through antisense oligonucleotides (ACT-UP1). The company targets cardiovascular, metabolic, CNS, and rare diseases.
Who are Arnatar Therapeutics's investors?
Arnatar Therapeutics's investors include 3E Bioventures Capital, F-Prime Capital Partners, Apricot Capital, Eight Roads Ventures, F-Prime Capital, Gaorong Ventures, Legend Star, New Alliance Capital.